NCT06927830 Frequency of Occurrence and Risk Factors of Postoperative Nausea and Vomiting During Elective C-section Under Spinal Anesthesia With Preventive Medication
| NCT ID | NCT06927830 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Liege |
| Condition | Nausea and Vomiting, Postoperative |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-03-19 |
| Primary Completion | 2026-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2025-03-19 with a primary completion date of 2026-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to learn about the incidence and risk factors of nausea and vomiting during planned caesarean section under spinal anesthesia. The main question it aims to answer is : What are the incidence and risks factors of postoperative nausea and vomiting (NV) during planned caesarean section under spinal anesthesia with administration of intrathecal morphine and multimodal antiemetic prophylaxis ? Patients who will be managed according to the standard protocol in use in the department will have to answer specific questions about NV in the post-interventional recovery room and on 2 further visits in the first 24 hours post-caesarean section.
Eligibility Criteria
Inclusion Criteria: Any patient requiring elective caesarean section under spinal anesthesia, at a gestational age \>37 weeks of amenorrhea in the context of a single-fetal pregnancy. Exclusion Criteria: Failure to understand the French language; Contraindication to locoregional anesthesia; Nausea and/or vomiting in the 24 hours preceding the procedure; Type 1 or type 2 insulin-requiring non-gestational diabetes; Allergy or contraindication to one of the products used in the usual management protocol; Severe preeclampsia; Height \<150 cm
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06927830 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Nausea and Vomiting, Postoperative. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06927830 currently recruiting?
Yes, NCT06927830 is actively recruiting participants. Contact the research team at tmichot@chuliege.be for enrollment information.
Where is the NCT06927830 trial being conducted?
This trial is being conducted at Chenée, Belgium, Liège, Belgium.
Who is sponsoring the NCT06927830 clinical trial?
NCT06927830 is sponsored by University of Liege. The trial plans to enroll 400 participants.